Gsk Share Discussion Threads

[zho] 31/1/2024 14:58

GSK's RSV vaccine success makes its shares look cheap

After years as a sector laggard, the company has decided to make a name for itself in immunisations

At this point, there’s no way to estimate the cost of resolving the [Zantac] saga, but with shares trading on just 10 times forward earnings for 2024, we’d argue GSK looks cheap for a company on the up. Buy.

[ianood] 31/1/2024 14:49

Yes, must say I'm eating humble pie!

[steeplejack] 31/1/2024 14:39

Nothing's changed over the decades.It requires the US market to determine the reaction to figures.The UK flounders without a Wall Street lead.

[pcok] 31/1/2024 14:26

Good results that point to a growing and increasingly profitable future. Not wishing to count chickens before hatching but could it be that the much maligned CEO has done a good job and managed to redirect this oil tanker into more rewarding waters. I for one think so. She took on a helluva big job and we seem to be seeing the hard work beginning to pay off. There ain't nothin like a Dame.

[rikky72] 31/1/2024 14:21

To be fair, things weren't too bad but then some woke up to Zantac and acted like GSK had put cyanide in all its marketed drugs :(

[patientcapital] 31/1/2024 13:49

All good things….

[careful] 31/1/2024 13:42

After years of waiting we are at last showing some form.
Things looking better after todays results.

[tuftymatt] 31/1/2024 13:20

This has done what DGE did yesterday!!

Good luck all 👍🏻

[lippy4] 31/1/2024 12:46

nice to buy at a low point and see it go up afterwards as the opposite can be regular happening..

[anhar] 31/1/2024 12:18

Yes of course, whatever it's called. From memory wasn't this the acq for which they paid something like a 100% premium over the pre bid price when nearly all bids go for way less than that?

I don't want to get in too close to any share in my income port. I think that doing so can blind investors to the bigger picture of eps, cash flow, debt, yield etc. thinking that some wonder drug, in this case, will be a nice earner. How many times have such hopes been dashed?

So over the years as an income investor I've become just a numbers player on the fundamentals of a share. I wouldn't know camlipixant from my behind and if I chose to invest that way it would lead me astray, causing a love affair with the share and losing investment perspective. I know FA about the drug industry and don't want to know either.

So I take very little interest in the fine detail of any of my many holdings, just enough to know what industry they're in to ensure diversification. After that, it's the three main indicators: numbers, numbers, numbers.

[tradermichael] 31/1/2024 12:02

Anhar, do you mean Bellus Health Inc.?

That acquisition provides GSK access to camlipixant, a potential best-in-class and highly selective P2X3 antagonist currently in phase III development for the first-line treatment of adult patients with refractory chronic cough. An excellent potential drug to boost the GSK portfolio of respiratory products.

[mattboxy] 31/1/2024 11:55

Quite a sudden turnaround is there some Zantac news?

[rikky72] 31/1/2024 10:49

Bellend! Let's hope it doesn't end up justifying that name

[mj19] 31/1/2024 10:45

Future looks good for sure! Think long term

[anhar] 31/1/2024 10:26

Welcome modest reduction in crushing debt burden. Small increase in divi anticipated for 2024 at 60p which is +3.4% on the 58p for 23. Forward yield at 1,520p is 3.9%.

Not too bad results looking at the whole picture but as a very long term holder and income investor, I don't really trust GSK that much. It has a patchy record.

Also, following the large acquisition of Bellend in the year, I see that they have forked out a further $1bn for yet another acq. after the year end. A partial sale of the HLN holding covers this cost though.

The general rule is that acqs are too often poor decisions and tend to destroy value. Not all but frequently.

[lippy4] 31/1/2024 10:08

in for some more, as a long time holder i like the movement with the share price even if its small at least its progress in the right direction..

[spacecake] 31/1/2024 09:44

The reaction is not ridiculous

4th quarter eps 8.6p
Dividend 16p

[rikky72] 31/1/2024 09:21

The reaction is faintly ridiculous yet not unexpected by anyone who's been following for a while. Still need evidence of more pipeline progress plus Zantac filed in the completed drawer before this rerates.

[tradermichael] 31/1/2024 09:17

Increased dividend of 16p declared for Q4 2023; 58p FY 2023; 60p expected for 2024

[tradermichael] 31/1/2024 08:36

GSK beats earnings expectations on blockbuster RSV jab
Ian Johnston in London

Strong vaccine sales powered British pharmaceutical company GSK to higher-than-expected earnings in 2023, as the company’s new RSV jab gained “blockbuster” status just over six months after its US launch.

Total sales rose 5 per cent year-on-year to £30.3bn, with adjusted operating profit of £8.8bn, ahead of analysts’ estimates. The company expects sales growth of 5 to 7 per cent in 2024, while it also raised its 2031 sales outlook to £38bn.

The business was helped by stronger than expected £1.2bn sales of Arexvy, its new vaccine for respiratory syncytial virus authorised in the US in May 2023, which has taken two-thirds of market share ahead of its only rival jab by Pfizer, while its shingles vaccine brought in £3.4bn.

[mj19] 31/1/2024 08:18

GSK, a pharmaceutical group, announced that 4Q adjusted EPS rose 25% on year to 28.9 pence and revenue was up 15% to 8.05 billion pounds, both at constant exchange rates. The company expects 2024 adjusted EPS growth of between 6% - 9%, compared with 16% in 2023.

[simon8] 31/1/2024 08:18

Really good results if i read them right, was expecting a lift in the share price .. well down we go, no surprise there - seems to happen so often with shares - good results and down they go.

[panache1] 31/1/2024 08:05

I'm in. 1525.60

[abdullla] 31/1/2024 08:04

Going down nothing new